Deutsche Bank AG Trims Stock Position in HealthEquity, Inc. (NASDAQ:HQY)

Deutsche Bank AG lessened its holdings in HealthEquity, Inc. (NASDAQ:HQY) by 5.9% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 111,251 shares of the company’s stock after selling 6,948 shares during the period. Deutsche Bank AG’s holdings in HealthEquity were worth $9,831,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Envestnet Asset Management Inc. lifted its stake in shares of HealthEquity by 2.8% during the fourth quarter. Envestnet Asset Management Inc. now owns 114,739 shares of the company’s stock valued at $11,009,000 after buying an additional 3,178 shares during the period. Bank of Montreal Can lifted its stake in shares of HealthEquity by 11.7% during the fourth quarter. Bank of Montreal Can now owns 12,756 shares of the company’s stock valued at $1,224,000 after buying an additional 1,338 shares during the period. Barclays PLC lifted its stake in shares of HealthEquity by 20.3% during the fourth quarter. Barclays PLC now owns 200,341 shares of the company’s stock valued at $19,223,000 after buying an additional 33,849 shares during the period. Mariner LLC lifted its stake in shares of HealthEquity by 1.8% during the fourth quarter. Mariner LLC now owns 13,309 shares of the company’s stock valued at $1,277,000 after buying an additional 239 shares during the period. Finally, XTX Topco Ltd purchased a new position in shares of HealthEquity during the fourth quarter valued at approximately $432,000. Hedge funds and other institutional investors own 99.55% of the company’s stock.

Insider Activity

In other news, Director Jon Kessler sold 134,183 shares of the firm’s stock in a transaction on Friday, June 6th. The shares were sold at an average price of $112.08, for a total value of $15,039,230.64. Following the transaction, the director owned 253,510 shares of the company’s stock, valued at approximately $28,413,400.80. This trade represents a 34.61% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Michael Henry Fiore sold 1,794 shares of the firm’s stock in a transaction on Monday, July 7th. The shares were sold at an average price of $101.73, for a total transaction of $182,503.62. Following the completion of the transaction, the executive vice president directly owned 53,225 shares in the company, valued at approximately $5,414,579.25. This represents a 3.26% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 291,744 shares of company stock valued at $32,705,007. Company insiders own 1.50% of the company’s stock.

HealthEquity Stock Performance

NASDAQ:HQY opened at $89.89 on Friday. The company has a quick ratio of 4.06, a current ratio of 4.06 and a debt-to-equity ratio of 0.50. The company has a market cap of $7.77 billion, a P/E ratio of 65.61, a P/E/G ratio of 1.35 and a beta of 0.54. HealthEquity, Inc. has a fifty-two week low of $72.79 and a fifty-two week high of $116.65. The firm’s 50 day moving average is $98.42 and its two-hundred day moving average is $97.35.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings results on Tuesday, June 3rd. The company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.81 by $0.16. The company had revenue of $330.80 million for the quarter, compared to the consensus estimate of $322.25 million. HealthEquity had a net margin of 9.80% and a return on equity of 11.01%. During the same quarter last year, the firm posted $0.80 earnings per share. Analysts expect that HealthEquity, Inc. will post 2.32 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on HQY. Deutsche Bank Aktiengesellschaft upped their price objective on shares of HealthEquity from $98.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, June 5th. Royal Bank Of Canada upped their price objective on shares of HealthEquity from $112.00 to $117.00 and gave the company an “outperform” rating in a research note on Wednesday, June 4th. Barrington Research upped their price objective on shares of HealthEquity from $112.00 to $125.00 and gave the company an “outperform” rating in a research note on Thursday, June 5th. Raymond James Financial reissued a “strong-buy” rating and set a $120.00 price objective (up previously from $115.00) on shares of HealthEquity in a research note on Tuesday, July 8th. Finally, The Goldman Sachs Group upped their price objective on shares of HealthEquity from $94.00 to $104.00 and gave the company a “neutral” rating in a research note on Wednesday, June 4th. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $118.55.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.